التداخل بين أملوديبين وأولميسارتان وأبريبيتانت

• Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect.

CYP3A Inhibitors : Co-administration of amlodipine with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.

Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment .

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.

CYP3A Inducers: No information is available on the quantitative effects of CYP3A inducers on amlodipine.